PECULIARITIES OF THE COURSE OF CHRONIC HEART FAILURE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND THE SIGNIFICANCE OF PROGNOSTIC MARKERS
Keywords:
galectin-3, H-FABR, type 2 diabetes mellitus, chronic heart failureAbstract
Relevance. Cardiovascular diseases remain the main cause of death and disability in patients with type 2 diabetes mellitus (DM 2) DM 2 aggravates the underlying mechanisms of atherosclerosis and heart failure.
Goal. To study the features of the course of CHF in patients with type 2 diabetes mellitus and
Material and methods. 80 patients (prospectively) with type 2 diabetes were examined at the Acad. V.V. Vakhidov.
Of these, there were 29 women and 51 men. The average age of men was 67 ± 4.2 years, and the average age of women was 64 ± 5.6 years. 10 patients with DM 2 without coronary artery disease of the corresponding age made up the control group.
The study used clinical and biochemical research methods (glycemia, glycated hemoglobin, ALT, AST, bilirubin, urea, creatinine, PTI, studies of CHF biomarkers (galectin-3, H-FABR), as well as instrumental methods of examination-ultrasound of internal organs, ECG, Echo-ECG, as well as statistical techniques.
Results. The mean values of galectin 3 and H-FABR in the preoperative period were normal in patients of groups 2 and 4, but were significantly high in patients of groups 1 and 3, that is, with a combination of DM 2 and CHF, approaching critical threshold values. Thus, the average values of galectin-3 in the 1st group of patients were within 8.68±0.04 ng/ml, and in the group 7.62±0.08 ng/ml. The average H-FABR data in group 1 reached 17.1±0.4 ng/ml, and in the group 13.5±0.7 ng/ml.
Conclusion. The increase in the concentration of Galectin-3 and H-FABR in all patients with type 2 DM with concomitant CHF, as well as the high sensitivity and specificity of the test, prove the value of this marker for diagnosing CHF in patients with type 2 DM.
References
Anderson RE, Brismar K, Ivert T. Only a minority of patients referred for elective coronary artery bypass surgery have risk factors diagnosed and treated according to established guidelines. // Diab Vasc Dis Res 2007; 4:112–6. 10.3132/dvdr.2007.028
Anderson RE, Klerdal K, Ivert T, et al. Are even impaired fasting blood glucose levels preoperatively associated with increased mortality after CABG surgery? /Eur Heart J 2005;26:1513–8. 10.1093/eurheartj/ehi182
Bansal N, Zelnick LR, Soliman EZ, Anderson A, Christenson R, DeFilippi C, et al. Change in cardiac biomarkers and risk of incident heart failure and atrial fibrillation in CKD: the chronic renal insufficiency cohort (CRIC) study. // Am J Kidney Dis. 2021; 77:907–19. doi: 10.1053/j.ajkd.2020.09.021.
Beckman JA, Paneni F, Cosentino F, Creager MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J. 2013; 34:2444–2452.
Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet. 2006; 368:29–36.
Bošnjak I, Selthofer-Relatić K, Včev A. Prognostic value of galectin-3 in patients with heart failure. //Dis Markers. 2015; 2015:690205. doi: 10.1155/2015/690205.
Brunner EJ, Shipley MJ, Witte DR, et al. Relation between blood glucose and coronary mortality over 33 years in the Whitehall study. // Diabetes Care 2006; 29:26–31. 10.2337/diacare.29.01.06. dc05-1405
Cecilia C. Low Wang, MD, Connie N. Hess, MD, MHS, William R. Hiatt, MD, and Allison B. Goldfine,Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes – Mechanisms, Management, and Clinical ConsiderationCirculation. Author manuscript; available in PMC 2017 Jun 14.Published in final edited form as:Circulation. 2016 Jun 14; 133(24): 2459–2502.doi: 10.1161/CIRCULATIONAHA.116.022194
Consultation WI Definition and diagnosis of diabetes. // International Diabetes Federation, 2006
de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. // Ann Med. 2011; 43:60–8. doi: 10.3109/07853890.2010.538080
George A, Bhatia RT, Buchanan GL, et al. Impaired glucose tolerance or newly diagnosed diabetes mellitus diagnosed during admission adversely affects prognosis after myocardial infarction: an observational study. // PLoS One 2015;10: e0142045. 10.1371/journal.pone.0142045
Holzmann MJ, Rathsman B, Eliasson B, et al. Long-Term prognosis in patients with type 1 and 2 diabetes mellitus after coronary artery bypass grafting. // J Am Coll Cardiol 2015; 65:1644– 52. 10.1016/j.jacc.2015.02.052
Jernberg T, Attebring MF, Hambraeus K, et al. The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). // Heart 2010; 96:1617–21. 10.1136/hrt.2010.198804
Lenzen M, Ryden L, Ohrvik J, et al.. Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro heart survey on diabetes and the heart. // Eur Heart J 2006;27:2969–74. 10.1093/eurheartj/ehl363
Lim CC, et al. With the “universal definition,” measurement of creatine kinase-myocardial band rather than troponin allows more accurate diagnosis of periprocedural necrosis and infarction after coronary intervention. //J. Am. Coll. Cardiol. 2011; 576:53–61.
Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, et al. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. // Eur J Epidemiol 2009; 24:659–67. 10.1007/s10654-009-9350-y
McCullough PA, Olobatoke A, Vanhecke TE. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. //Rev Cardiovasc Med. 2011; 12:200–10. doi: 10.3909/ricm0624
Motiwala SR, Szymonifka J, Belcher A, Weiner RB, Baggish AL, Sluss P, et al. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. //Eur J Heart Fail. 2013; 15:1157–63. doi: 10.1093/eurjhf/hft075.
Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. // Diabetes Res Clin Pract 2017; 128:40–50. 10.1016/j.diabres.2017.03.024
Sumin AN, Bezdenezhnykh NA, Bezdenezhnykh AV, et al. The role of newly diagnosed diabetes mellitus for poor in-hospital prognosis of coronary artery bypass grafting. // Diabetes mellitus 2018; 21:344–55. 10.14341/DM9585
von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. // J Clin Epidemiol 2008; 61:344–9. 10.1016/j.jclinepi.2007.11.008
Курята А.В., Кушнир Ю.С. Уровень и динамика Галектина-3 при хронической сердечной недостаточности с сохраненной систолической функцией левого желудочка на фоне использования петлевых диуретиков // https://www.webcardio.org/urovenj-y-dynamyka- ghalektyna-3-pry-khronycheskoj-serdechnoj-nedostatochnosty-s-sokhranennoj- systolycheskoj-funktsyej-levogho-zheludochka-na-fone-yspoljzovanyya-petlevykh- dyuretykov.aspx
Щукин Ю. В., Березин И. И., Е. А. Медведева, Е. И. Селезнев, и др. О значении галектина-3 как маркер и медиатора эндогенного воспаления и окислительно- нитролизирующего стресса у больных с ХСН https://doi.org/10.15829/1560-4071-2013-2- 45-49
